Publication of Phase 1 data on SDC-1801 in BJCP

AI SummaryClose X

Sareum Holdings PLC has announced the publication of Phase 1 clinical data for its lead asset, SDC-1801, in the British Journal of Clinical Pharmacology, confirming a well-tolerated safety profile across all doses tested and demonstrating clear TYK2/JAK1 target engagement. The pharmacokinetic data, showing a half-life of approximately 15-27 hours, supports once or twice-daily oral dosing, with computational modelling indicating that 70mg twice-daily achieves exposure levels comparable to brepocitinib without observed side effects. This data is informing the ongoing toxicology programme and formulation optimisation, with a complete Phase 2-enabling regulatory package anticipated by year-end, reinforcing confidence in SDC-1801's potential as a best-in-class therapy for autoimmune diseases.

Disclaimer*

UK 100

Latest directors dealings